Scientific Program Committee

CROI 2008 Session 39
k Wednesday, 10 am-12 noon; Auditorium
CME
Session 39–Oral Abstracts
Cardiovascular Risk, Mortality and TB
Complicating HIV Infections
Moderators:
Ian Sanne, Univ of the Witwatersrand, Johannesburg, South Africa
Christine Wanke, Tufts Univ Sch of Med and Tufts–New England Med Ctr, Boston,
MA, US
10:00 139 Elevated Levels of Interleukin-6 and D-dimer Are
Associated with an Increased Risk of Death in Patients
with HIV
Lewis Kuller and SMART Study Group
Univ of Pittsburgh, PA, US
10:15 140 HIV Activates Markers of Cardiovascular Risk in a
Randomized Treatment Interruption Trial: STACCATO
Alexandra Calmy* 1 , A Nguyen1 , F Montecucco1 ,
A Gayet-Ageron1 , F Burger1 , F Mach1 , A Carr2 , S Ubolyam3 ,
B Hirschel1 , and J Ananworanich3,4 for the STACCATO Study Team
1 2 Geneva Univ Hosp, Switzerland; St Vincent’s Hosp, Sydney,
Australia; 3HIV Netherlands Australia Thailand Res Collaboration,
Bangkok; and 4South East Asia Res Collaboration with Hawaii,
Bangkok, Thailand
10:30 141 Age- and Sex-specific Death Rates in ART-naïve
Patients with CD4 Count above 350 cells/mm3 Compared with the General Population
Rebecca Lodwick* 1 , K Porter2 , C Sabin1 , B Ledergerber3 ,
A Cozzi-Lepri1 , P Khaykin4 , A Mocroft1 , L Jacobson5 , S de Wit6 ,
A Phillips1 , and Study Group on Death Rates at High CD4 Count in
Antiretroviral-naïve Patients
1 2 Univ Coll London, UK; Med Res Council Clinical Trials Unit,
London, UK; 3Univ Hosp Zurich, Switzerland; 4JW Goethe Univ,
Frankfurt, Germany; 5Johns Hopkins Univ, Baltimore, MD, US; and
6St Pierre Univ Hosp, Brussels, Belgium
10:45 142 Immediate vs Deferred ART in the Setting of Acute
AIDS-related Opportunistic Infection: Final Results of
a Randomized Strategy Trial, ACTG A5164
Andrew Zolopa* 1 , J Andersen2 , L Komarow2 , A Sanchez3 ,
C Suckow4 , I Sanne5 , E Hogg6 , W Powderly7 , and ACTG A5164
Study Team
1 2 Stanford Univ, Palo Alto, CA, US; Statistical and Data Analysis
Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of Southern
California, Los Angeles, US; 4Frontier Sci & Tech Res Fndn,
Buffalo, NY, US; 5Univ of the Witswatersrand, Johannesburg, South
Africa; 6Social & Sci Systems, Silver Spring, MD, US; and 7Univ Coll Dublin, Ireland
11:00 143 Exogenous Re-infection with Multidrug- and
Extensively Drug-resistant TB among TB/HIV
Co-infected Patients in Rural South Africa
J Andrews1 , Neel Gandhi* 2 , P Moodley3 , S Shah2 , L Bohlken3 ,
T Moll4 , M Pillay3 , G Friedland1 , W Sturm3 , and Tugela Ferry Care
and Res Collaboration
1 2 Yale Univ Sch of Med, New Haven, CT, US; Albert Einstein Coll of
Med, Bronx, NY, US; 3Nelson R Mandela Sch of Med, Durban, South
Africa; and 4Philanjalo and Church of Scotland Hosp, Tugela Ferry,
South Africa
11:15 144 HIV Infection and Drug-resistant TB in Ukraine: A
Threatening Convergence of 2 Epidemics?
I Dubrovina1 , K Miskinis2 , S Lyepshina3 , Y Yann4 , H Hoffmann5 ,
R Zaleskis6 , P Nunn7 , and Matteo Zignol* 7
1 2 WHO, Project Office, Donetsk, Ukraine; WHO, Country Office,
Kiev, Ukraine; 3Donetsk State Med Univ, Ukraine; 4Donetsk TB
Reference Lab, Ukraine; 5Inst of Microbio and Lab Med, Asklepios
Fachkliniken München-Gauting, Germany; 6WHO, European
Regional Office, Copenhagen, Denmark; and 7WHO Headquarters,
Geneva, Switzerland
11:30 145 The Influence of TB on Early Mortality in the Themba
Lethu Clinical Cohort, Johannesburg, South Africa
Daniel Westreich* 1 , S Badal-Faesen2 , B Malope2 , D Rubel2 ,
Z Akiy2 , P MacPhail2 , A Van Rie1 , and I Sanne2 1Univ of North Carolina at Chapel Hill, Sch of Publ Hlth, US and
2Univ of the Witwatersrand, Johannesburg, South Africa
11:45 146LB Effects of 18-Month Physiological GH Replacement in
Relatively GH-deficient Patients with HIV Lipodystrophy
J Lo, S You, B Canavan, J Liebau, G Beltrani, P Koutkia, H Lee, and
Steven Grinspoon*
Massachusetts Gen Hosp, Boston, US
c Wednesday, 1-4 pm; Poster Hall
Poster Abstracts
(see full session listings starting on page 25)
Session 53. HIV-1 Macrophage Studies
Session 54. Co-infection: Virus/Virus Interactions
Session 55. Viral Reservoirs
Session 56. Viral Transmission: Molecular Studies
Session 63. Studies on Elite Controllers and Exposed Uninfected
Session 64. Studies of Non-progressive Infection
Session 65. Lymphocyte Depletion in the Gut
Session 66. Monocyte/Macrophage Studies
Session 71. Co-infection with HCV
Session 72. PML and JC Virus
Session 78. B Cell and Immunoglobulin Studies
Session 79. Studies on NK and Plasmacytoid Dendritic Cells
Session 80. HIV Vaccines: Induction of Neutralizing Antibodies and Responses
Session 81. HIV Vaccines: Induction of Cellular Immune Responses
Session 82. HIV Vaccines: Novel Viral Vectors
Session 83. HIV Vaccines: Clinical Trials
Session 89. Expanding HIV Testing
Session 90. Behavioral Risk in HIV Infection
Session 94. Preclinical and Clinical Studies of Topical and Oral PrEP
Session 101. Special Considerations in Laboratory Studies for Children
Session 102. Transmission and Diagnosis of HIV Infection in Infants and Children
Session 103. Immune Response in Children
Session 104. Viral and Host Factors Associated with Pediatric Disease Progression
Session 110. Risk, Timing and Viral Genetics of MTCT
Session 111. Co-infections during Pregnancy
Session 120. Immune-Based Therapies: Cytokines
Session 121. Immune-Based Therapies: Therapeutic Vaccines
Session 122. Immune-Based Therapies: Novel Approaches
Session 129. ART: Adherence
Session 130. HIV Care in Different Settings
Session 133. Risk Factors for Lost-to-Follow-up in Resource-limited Settings
Session 134. Complications in Resource-limited Settings
Session 139. New Resistance Technologies
Session 140. HIV-1 Drug Resistance: Genital Shedding and Recombination
Session 141. HIV-2 Drug Resistance
Session 151. Diagnosis and Monitoring Using Dried Specimens
Session 159. Impact on Cardiac Function
Session 160. Hypersensitivity Reactions: Other Drug Toxicities
Session 161. in vitro and Animal Studies of Metabolic Toxicity
Session 162. ART Toxicity in Resource-limited Settings
Session 163. TB Screening and Diagnostics
Session 164. HIV/TB Co-infection
Session 165. TB-associated Immune Reconstitution Inflammatory Syndrome
Session 166. Cryptococcal and Herpesvirus Infections
Session 167. Infectious Complications
Session 168. Malignancies
Program 21
Wednesday
February 6 Sessions